Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Diasome Pharmaceuticals, a clinical stage diabetes therapeutics company, has appointed David King as its new chairman of the board.
Subscribe to our email newsletter
Previously, Mr King has served as the CEO of Principia Pharmaceutical, which was acquired by Human Genome Sciences, and as president of Delsys Pharmaceutical, which was acquired by Elan. Currently, he is a venture partner in Quaker BioVentures, and serves as chairman of Xencor.
Len Rosenberg, CEO of Diasome, said: “We’re excited to bring David’s invaluable experience to Diasome. He has been a part of several successful venture-backed companies in the Philadelphia region, and we know he will be an incredibly valuable asset as we embark on late-stage testing of our lead product.”